Turkovac

Turkovac
Vaccine description
Target	SARS-CoV-2
Vaccine type	Inactivated
Clinical data
Other names	Erucov-Vac
Routes of; administration	Intramuscular
Legal status
Legal status	Full list of Turkovac authorizations;
Identifiers
CAS Number	2695585-27-2;

Turkovac^[2] (pronunciation: ['tɜ:rkəvæk]) is a COVID-19 vaccine developed by Turkish Ministry of Health and Erciyes University.

Clinical trials

In November 2020, Turkovac started on phase I trials with 44 participants in Turkey.^[3]

In February 2021, Turkovac started on phase II trials with 250 participants in Turkey.^[4]

In June 2021, Turkovac started on phase III trials with 40,800 participants in Turkey.^[5] As of 2023^[update] phase III trials continue.^[6]

Authorization

On 25 November 2021, the Turkish Minister of Health reported that Turkovac's application for emergency use authorization had been filed.^[7] On 22 December, Turkish President Recep Tayyip Erdogan announced the emergency use approval of Turkovac.^[8]

References

^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
^ Cakmak BN (22 June 2021). "Turkey names home-grown COVID-19 jab Turkovac". Anadolu Agency.
^ Clinical trial number NCT04691947 for "Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine Erucov-Vac" at ClinicalTrials.gov
^ Clinical trial number NCT04824391 for "Efficacy, Immunogenicity and Safety of Inactivated Erucov-Vac Compared With Placebo in COVID-19 " at ClinicalTrials.gov
^ "Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (Turkovac) Versus the CoronaVac Vaccine". ClinicalTrials.gov. 28 June 2021. NCT04942405. Retrieved 29 June 2021.
^ "ClinicalTrials.gov". www.clinicaltrials.gov. Retrieved 16 January 2024.
^ "Turkey issues emergency-use authorization for its domestically produced vaccine". The New York Times. 22 December 2021. Retrieved 28 December 2021.
^ "Turkey authorises use of own Turkovac Covid-19 vaccine". France 24. 23 December 2021. Retrieved 24 December 2021.

Scholia has a profile for TURKOVAC (Q106532118).

This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.

This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.

[1] "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).

[2] Cakmak BN (22 June 2021). "Turkey names home-grown COVID-19 jab Turkovac". Anadolu Agency.

[3] Clinical trial number NCT04691947 for "Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine Erucov-Vac" at ClinicalTrials.gov

[4] Clinical trial number NCT04824391 for "Efficacy, Immunogenicity and Safety of Inactivated Erucov-Vac Compared With Placebo in COVID-19 " at ClinicalTrials.gov

[5] "Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (Turkovac) Versus the CoronaVac Vaccine". ClinicalTrials.gov. 28 June 2021. NCT04942405. Retrieved 29 June 2021.

[6] "ClinicalTrials.gov". www.clinicaltrials.gov. Retrieved 16 January 2024.

[7] "Turkey issues emergency-use authorization for its domestically produced vaccine". The New York Times. 22 December 2021. Retrieved 28 December 2021.

[8] "Turkey authorises use of own Turkovac Covid-19 vaccine". France 24. 23 December 2021. Retrieved 24 December 2021.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]